Insulin analogs with improved pharmacokinetic profiles

Advanced Drug Delivery Reviews

Volumn 35, Issue 2-3, 1999, Pages 307-335

  Brange, Jens ^a   Vølund, Aage ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Albumin binding insulin; Aspart insulin; Basal bolus treatment; Biological potency; Diabetes therapy; Fatty acid acylated insulin; Human insulin; Lispro insulin; Monomeric insulin; NN304; Physicochemical properties; Proinsulin

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN; PROINSULIN;

DIABETES MELLITUS; DRUG ABSORPTION; DRUG PROTEIN BINDING; GLUCOSE BLOOD LEVEL; INSULIN RELEASE; INSULIN TREATMENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0032969538     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00079-9     Document Type: Review

References (148)

1. Goeddel D.V., Kleid D.G., Bolivar F., Heyneker H.L., Yansura D.G., Crea R., Hirose T., Kraszewski A., Itakura K., Riggs A.D. Expression in escherichia coli of chemically synthesized genes for human insulin. Proc. Natl. Acad. Sci. USA. 76:1979;106-110.
2. Keen H., Glynne A., Pickup J.C., Viberti G.C., Bilous R.W., Jarrett R.J., Marsden R. Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men. Lancet. 2:1980;398-401.
3. D. Brandenburg, Insulin chemistry today: from the first synthesis to tailor-made derivatives and biosynthetic analogues, in: H. Rifkin, J.A. Colwell, S.I. Taylor (Eds.), Diabetes 1991, Elsevier, Amsterdam, 1991, pp. 76-81.
4. Gardner D.F., Arakaki R.F., Podet E.J., Nell L.J., Thomas J.W., Field J.B. Pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessment using a glucose clamp technique. J. Clin. Endocrinol. Metab. 63:1986;689-694.
5. Roy B., Chou M.C.Y., Field J.B. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics. J. Clin. Endocrinol. Metab. 50:1980;475-479.
6. Owens D.R., Vora J.P., Heding L.G., Luzio S., Ryder R.E.J., Atiea J., Hayes T.M. Human, porcine and bovine Ultralente insulin: subcutaneous administration in normal man. Diabetic Med. 3:1986;326-329.
7. Francis A.J., Hanning I., Alberti K.G.M.M. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia. Diabetes Res. 3:1986;263-268.
8. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329 (1993) 977-986.
9. Ullrich A., Shine J., Chirgwin J., Pictet R., Tischer E., Rutter W., Goodman H.M. Rat insulin genes: construction of plasmids containing the coding sequences. Science. 196:1977;1313-1319.
10. Chance R.E., Kroeff E.P., Hoffmann J.A., Frank B.H. Chemical, physical and biological properties of biosynthetic human insulin. Diabetes Care. 4:1981;147-154.
11. J. Markussen, U. Damgaard, I. Diers, N. Fiil, M.T. Hansen, P. Larsen, F. Norris, K. Norris, O. Schou, L. Snel, L. Thim, H.O. Voigt, Biosynthesis of human insulin in yeast via single-chain precursors, in: D. Theodoropoulos (Ed.), Peptides 1986, de Gruyter, Berlin, 1986, pp. 189-194.
12. Thim L., Hansen M.T., Norris K., Hoegh I., Boel E., Forstrom J., Ammerer G., Fiil N.P. Secretion and processing of insulin precursors in yeast. Proc. Natl. Acad. Sci. USA. 83:1986;6766-6770.
13. Brange J., Diers I., Hansen J., Hansen M.T., Havelund S., Melberg S.G., Norris F., Norris K., Snel L., Voigt H.O. Monomeric insulins by protein engineering (abstract). Protein Eng. 1:1987;250.
14. Brange J., Diers I., Hansen J., Hansen M.T., Havelund S., Melberg S.G., Norris F., Norris K., Ribel U., Snel L., Sørensen A.R., Voigt H.O. Monomeric insulins are absorbed three times faster from subcutis than human insulin (abstract). Diabetes. 36(Suppl. 1):1987;77A.
15. Brange J., Ribel U., Hansen J., Dodson G., Hansen M.T., Havelund S., Melberg S.G., Norris F., Norris K., Snel L., Sørensen A.R., Voigt H.O. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 333:1988;679-682.
16. Markussen J., Diers I., Engesgaard A., Hansen M.T., Hougaard P., Langkjaer L., Norris K., Ribel U., Sørensen A.R., Sørensen E., Voigt H.O. Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30. Protein Eng. 1:1987;215-223.
17. Markussen J., Diers I., Hougaard P., Langkjaer L., Norris K., Snel L., Sørensen A.R., Sørensen E., Voigt H.O. Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng. 2:1988;157-166.
18. Vora J.P., Owens D.R., Burch A., Dolben J., Atiea J., Dean J., Brange J. Comparison of a monomeric insulin analog and neutral soluble insulin in normal subjects (abstract). Diabetic Med. 4:1987;558A.
19. Vora J.P., Owens D.R., Dolben J., Atiea J.A., Dean J.D., Kang S., Burch A., Brange J. Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects. Br. Med. J. 297:1988;1236-1239.
20. Jørgensen S., Vaag A., Langkjær L., Hougaard P., Markussen J. NovoSol Basal: pharmacokinetics of a soluble long acting insulin analogue. Br. Med. J. 299:1989;415-419.
21. Kang S., Owens D.R., Vora J.P., Brange J. Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes. Lancet. 335:1990;303-306.
22. R.D. DiMarchi, J.P. Mayer, L. Fan, D.N. Brems, B.H. Frank, L.K. Green, Synthesis of a fast-acting insulin based on structural homology with insulin-like growth factor 1, in: J.A. Smith, J.E. Rivier (Eds.), Peptides XII (Proceedings of the 12th American Peptide Symposium), Escom, Leiden, 1992, pp. 26-28.
23. Balschmidt P., Brange J. Fast acting human insulin analogues with a single amino acid deletion in the B-chain (abstract). Diabetologia. 35(Suppl 1):1992;A4.
24. Markussen J., Havelund S., Kurtzhals P., Andersen A.S., Halstrøm J., Larsen U.D., Ribel U., Schäffer L., Vad K., Jonassen I. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia. 39:1996;281-288.
25. Kurtzhals P., Havelund S., Jonassen I., Kiehr B., Larsen U.D., Ribel U., Markussen J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312:1997;725-731.
26. Home P.D., Pickup J.C., Keen H., Alberti K.G.M.M., Parsons J.A., Binder C. Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the meal time dose. Metabolism. 30:1981;439-442.
27. Dimitriades G.D., Gerich J.E. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 6:1983;374-377.
28. Blundell T., Dodson G., Hodgkin D., Mercola D. Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv. Protein Chem. 26:1972;279-402.
29. Binder C. Absorption of injected insulin. Acta Pharmacol. Toxicol. Suppl. 2:1969;1-87.
30. 35S) sulfated insulin: immunological and biological properties of the isolated electrophoretic components. Horm. Metab. Res. 3:1971;207-212.
31. Adams M.J., Blundell T.L., Dodson E.J., Dodson G.G., Vijayan M., Baker E.N., Harding M.M., Hodgkin D.C., Rimmer B., Sheat S. Structure of rhombohedral 2 zinc insulin crystals. Nature. 224:1969;491-495.
32. DiMarchi R., Chance R.E., Long H.B., Shields J.E., Slieker L.J. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm. Res. 41(Suppl. 2):1994;93-96.
33. Home P.D., Thow J.C., Tunbridge F.K. Insulin treatment: a decade of change. Br. Med. Bull. 45:1989;92-110.
34. Brange J., Owens D.R., Kang S., Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 13:1990;923-954.
35. Vølund Aa., Brange J., Jensen I., Markussen J., Ribel U., Sørensen A.R., Schlichtkrull J. In vitro and in vivo potency of insulin analogues designed for clinical use. Diabetic Med. 8:1991;839-847.
36. Slieker L.J., Brooke G.S., DiMarchi R.D., Flora D.B., Green L.K., Hoffmann J.A., Long H.B., Fan L., Shields J.E., Sundell K.L., Surface P.L., Chance R.E. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia. 40:1997;S54-S61.
37. Galloway J.A., Hooper S.A., Spradlin C.T., Howey D.C., Frank B.H., Bowsher R.R., Anderson J.H. Biosynthetic human proinsulin. Review of chemistry, in vitro receptor binding, animal and human pharmacology studies, and clinical experience. Diabetes Care. 15:1992;666-692.
38. B.H. Frank, J.M. Pettee, R.E. Zimmerman, P.J. Burck, The production of human proinsulin and its transformation to human insulin and C-peptide, in: D.H. Rich, E. Gross (Eds.), Peptides: Synthesis-Structure-Function, Piece Chemical Co., Rockford, IL, 1981, pp. 729-738.
39. Heinemann L., Heise T., Klepper A., Ampudia J., Bender R., Starke A.A.R. Time action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin. Diabete Metabol. 21:1995;415-419.
40. J. Brange, K. Drejer, J.F. Hansen, S. Havelund, N.C. Kaarsholm, S.G. Melberg, A.R. Sørensen, Design of novel insulins with changed self-association and ligand binding properties, in: H. Blöcker, J. Collins, R.D. Schmid, D. Schomburg (Eds.), Advances in Protein Design, International Workshop 1988, VCH, Weinheim, 1989, pp. 139-144.
41. Coates P.A., Mukherjee S., Luzio S., Srodzinski K.A., Kurzhals R., Roskamp R., Owens D.R. Pharmacokinetics of a 'long-acting' human insulin analogue (HOE901) in healthy subjects (abstract). Diabetes. 44(Suppl. 1):1995;130A.
42. M. Dreyer, M. Pein, M. Schmidt, B. Heldtmann, M. Schluzen, D. Rosskamp, Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31,B32)-human insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique, in: 15th International Diabetes Federation Congress, November 6-11, Kobe, 1994, p. 252 (abstract).
43. Myers S.R., Yakubu-Madus F.E., Johnson W.T., Baker J.E., Cusick T.S., Williams V.K., Tinsley F.C., Kriauciunas A., Manetta J., Chen V.J. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes. 46:1997;637-642.
44. Howey D.C., Woodworth J.R., Owsher R.R., Eviergo J. Pharmacokinetic and glucodynamic assessment of N-palmitoyl, Lys(B29) human insulin in healthy volunteers (abstract). Diabetologia. 40(Suppl. 1):1997;A354.
45. Stoll R.W., Touber J.L., Winterscheid L.C., Ensinck J.W., Williams R.H. Hypoglycemic activity and immunological half-life of porcine insulin and proinsulin in baboons and swine. Endocrinology. 88:1971;714-717.
46. Markussen J., Hougaard P., Ribel U., Sørensen A.R., Sørensen E. Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng. 1:1987;205-213.
47. C. Binder, A theoretical model for the absorption of soluble insulin, in: P. Brunetti, K.G.M.M. Alberti, A.M. Albisser, K.D. Hepp, M.M. Benedetti (Eds.), Artificial Systems for Insulin Delivery, Raven, New York, 1983, pp. 53-57.
48. Bentley G.A., Brange J., Derewenda Z., Dodson E.J., Dodson G.G., Markussen J., Wilkinson A.J., Wollmer A., Xiao B. Role of B13 Glu in insulin assembly. The hexamer structure of recombinant mutant (B13 Glu>Gln) insulin. J. Mol. Biol. 228:1992;1163-1176.
49. Kurtzhals P., Kiehr B., Sørensen A.R. The cobalt(III) insulin hexamer is a prolonged-acting insulin prodrug. J. Pharm. Sci. 84:1995;1164-1168.
50. Kurtzhals P., Ribel U. Action profile of cobalt(III)-insulin. A novel principle of protraction of potential use for basal insulin delivery. Diabetes. 44:1995;1381-1385.
51. Shoelson S.E., Lu Z.-X., Parlautan L., Lynch C.S., Smith G., Weiss M.A. Mutations at the dimer, hexamer, and receptor-binding surfaces of insulin independently affect insulin-insulin and insulin-receptor interactions. Biochemistry. 31:1992;1757-1767.
52. Baker E.N., Blundell T.L., Cutfield J.F., Cutfield S.M., Dodson E.J., Dodson G.G., Hodgkin D.M., Hubbard R.E., Isaacs N.W., Reynolds C.D., Sakabe K., Sakabe N., Vijayan N.M. The structure of 2Zn pig insulin crystals at 1.5 Å resolution. Philos. Trans. R. Soc. 319:1988;369-456.
53. Derewenda U., Derewenda Z., Dodson E., Dodson G.G., Reynolds C.D., Smith G.D., Sparks C., Swenson D. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature. 338:1989;594-596.
54. Kaarsholm N.C., Ko H.-C., Dunn M.F. Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin and miniproinsulin. Biochemistry. 28:1989;4427-4435.
55. Brems D.N., Alter L.A., Beckage M.J., Chance R.E., DiMarchi R.D., Green L.K., Long H.B., Pekar A.H., Shields J.E., Frank B.H. Altering the association properties of insulin by amino acid replacement. Protein Eng. 5:1992;527-533.
56. Melberg S.G., Johnson W.C. Jr. Changes in secondary structure follows the dissociation of human insulin hexamers: a circular dichroism study. Proteins. 8:1990;280-286.
57. B29-insulin: dissociation of a protein-ligand complex. Protein Sci. 5:1997;2521-2531.
58. B29-human insulin. Structure. 3:1995;615-622.
59. K. Wiefels, B. Kuglin, L.N. Jorgensen, F.A. Gries, Insulin kinetics and dynamics in insulin-dependent diabetic patients after injections of human insulin or the insulin analogues X14 and X14+Zn, in: M. Berger, F.A. Gries (Eds.), Frontiers in Insulin Pharmacology, Thieme, Stuttgart, 1993, pp. 102-109.
60. J.A. Lutterman, E. Pijpers, P.M. Netten, L.N. Jørgensen, Glycaemic control in IDDM patients during one day with injection of human insulin or the insulin analogues insulin X14 and insulin X14 (+Zn), in: M. Berger, F.A. Gries (Eds.), Frontiers in Pharmacology, Thieme, Stuttgart, 1993, pp. 102-109.
61. Howey D.C., Bowsher R.R., Brunelle R.L., Woodworth J.R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 43:1994;396-402.
62. B29-insulin hexamers: a comparison study. Pharm. Res. 14:1997;25-36.
63. 1H-NMR assignments for the aromatic region of several biologically active, monomeric insulins including native human insulin. Biochim. Biophys. Acta. 1053:1990;63-73.
64. 1H NMR spectrum of the native human insulin monomer. Evidence for conformational differences between the monomer and aggregated forms. J. Biol. Chem. 265:1990;5448-5452.
65. 13C labeling with application to protein design. Biochemistry. 30:1991;7373-7389.
66. Brange J., Dodson G.G., Xiao B. Designing insulin for diabetes therapy by protein engineering. Curr. Opin. Struct. Biol. 1:1991;934-940.
67. Xiao B., Dodson G.G., Dodson E.J., Clarkson J., Turkenburg J., Derewenda U., Brady L. Mutant insulin crystal packing. J. Cryst. Growth. 122:1992;144-151.
68. Whittingham J.L., Edwards D.J., Antson A.A., Clarkson J.M., Dodson G.G. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 Pro→Asp insulin analogues. Biochemistry. 37:1998;11516-11523.
69. Whittingham J.L., Havelund S., Jonassen I. Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry. 36:1997;2826-2831.
70. Brange J., Andersen L., Laursen E.D., Meyn G., Rasmussen E. Toward understanding insulin fibrillation. J. Pharm. Sci. 86:1997;517-525.
71. Lougheed W.D., Zinman B., Strack T.R., Janis L.J., Weymouth A.B., Bernstain E.A., Korbas A.M., Frank B.H. Stability of insulin lispro in insulin infusion systems. Diabetes Care. 20:1997;1061-1065.
72. Zinman B., Tildesley H., Chiasson J.L., Tsui E., Strack T. Insulin lispro in CSII. Result of a double-blind crossover study. Diabetes. 46:1997;440-443.
73. Brange J., Langkjær L. Chemical stability of insulin. 3. Influence of excipients, formulation and pH. Acta Pharm. Nord. 4:1992;149-158.
74. DeFilippis M.R., Bakaysa D.L., Yongman K.M., Radziuk J., Frank B.H. Preparation and characterization of neutral protamine lispro (NPL) suspension (abstract). Diabetes. 45(Suppl. 2):1996;74A.
75. P. Balschmidt, Crystals of AspB28 human insulin and preparations containing such crystals, US patent No. 5547930, 1996.
76. D.R. Owens, S. Kang, S. Luzio, P. Coates, Clinical results of phase I studies with insulin analogues, in: M. Berger, F.A. Gries (Eds.), Frontiers in Insulin Pharmacology, Thieme, Stuttgart, 1993, pp. 79-86.
77. Brange J. The new era of biotech insulin analogues. Diabetologia. 40:1997;S48-S53.
78. Shaw K. Insulin lispro: insulin with a rapid onset of action. Prescriber. 8:1997;29-32.
79. Ribel U., Hougaard P., Drejer K., Sørensen A.R. Equivalent in vivo biological activity of insulin analogues and human insulin despite different in vitro potencies. Diabetes. 39:1990;1033-1039.
80. Polonsky K.S., Given B.D., Cauter E.V. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J. Clin. Invest. 81:1988;442-448.
81. D.R. Owens, Human Insulin: Clinical and Pharmacological Studies in Normal Man, Medical and Technical, Lancaster, UK, 1986.
82. Home P.D., Massi-Benedetti M., Shepherd G.A., Hanning I., Alberti K.G.M.M., Owens D.R. A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique. Diabetologia. 22:1982;41-45.
83. Binder C., Lauritzen T., Faber O., Pramming S. Insulin pharmacokinetics. Diabetes Care. 7:1984;188-199.
84. Seipke G., Geisen K., Neubauer H.P., Pittius C., Rosskamp R., Schwabe D. New insulin preparations with prolonged profiles: A21-modified arginine insulins (abstract). Diabetologia. 35(Suppl. 1):1992;A4.
85. Heinemann L., Heise T., Jorgensen L.N., Starke A.A.R. Action profile of rapid acting insulin analogue: human insulin B28Asp. Diabetic Med. 10:1993;535-539.
86. Kang S., Brange J., Burch A., Vølund A., Owens D.R. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care. 14:1991;942-948.
87. B28) in healthy subjects. Diabetes Care. 14:1991;1057-1065.
88. B29-human insulin - assessed in a conscious pig model. Diabetes. 46:1997;548-556.
89. Howey D.C., Bowsher R.R., Brunelle R.L., Rowe H.M., Santa P.F., Downing-Shelton J., Woodworth J.R. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin. Pharmacol. Ther. 58:1995;459-469.
90. Trajanoski Z., Wach P., Kotanko P., Ott A., Skraba F. Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues. Biomed. Tech. 38:1993;224-231.
91. Woodworth J., Howey D., Bowsher R., Lutz S., Santa P., Brady P. [Lys(B28), Pro(B29)] human insulin (K): dose-ranging vs. Humulin R (H) (abstract). Diabetes. 42(Suppl. 1):1993;54A.
92. ter Braak E.W., Woodworth J.R., Bianchi R., Cerimele B., Erkelens D.W., Thijssen J.H.H., Kurtz D. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 19:1996;1437-1440.
93. Heinemann L., Weyer C., Rauhaus M., Heinrichs S., Heise T. Variability of the metabolic effect of s.c. injected regular insulin and the rapid acting insulin-analogue B28Asp (abstract). Diabetes. 46(Suppl. 1):1997;330A.
94. 125I-insulin absorption and blood glucose concentration. Diabetologia. 17:1979;291-295.
95. Holman R.R., Steemson J. OPID 174: a novel long-acting insulin preparation (abstract). Diabetic Med. 6(Suppl. 1):1989;A41.
96. Hamilton-Wessler M., Ader M., Getty L., Markussen J., Bergman R.N. Glucose turnover profiles during continuous intravenous infusion of long-acting insulin NN304 (abstract). Diabetologia. 39(Suppl. 1):1996;A24.
97. Hamilton-Wessler M., Ader M., Dea M., Moore D., Markussen J., Bergman R. Dose response with long-acting insulin analog NN304 follows analog dynamics in hindlimb lymph in dogs (abstract). Diabetologia. 40(Suppl. 1):1997;A10.
98. ε-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Diabetologia. 41:1998;116-120.
99. Fineberg N.S., Fineberg S.E., Anderson J.H., Birkett M.A., Gibson R.G., Hufferd S. Immunologic effects of insulin lispro [Lys (B28),Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes. 45:1996;1750-1754.
100. Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab. Rev. 8:1992;259-286.
101. Ebeling P., Tuominen J.A., Koivisto V.A. Insulin analogues and carcinoma of the breast. Diabetologia. 39:1996;124-125.
102. J.H. Anderson, Jr., R.L. Brunelle, V.A. Koivisto, M.E. Trautmann, L. Vignati, R. DiMarchi, Multicenter Insulin Lispro Study Group, Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment, Diabetes 46 (1997) 265-270.
103. Pfutzner A., Kustner E., Forst T., Schulze-Schleppinghoff B., Trautmann M.E., Haslbeck M., Schatz H., Beyer J. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp. Clin. Endocrinol. 104:1996;25-30.
104. Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., Anderson J.H. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care. 20:1997;1827-1832.
105. Holleman F., Hoekstra J.B.L. Insulin lispro. N. Engl. J. Med. 337:1997;176-183.
106. Pampanelli S., Torlone E., Lalli C., del Sindaco P., Ciofetta M., Lepore M., Bartocci L., Brunetti P., Bolli G.B. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic β-cell function. Diabetes Care. 18:1995;1452-1459.
107. Torlone E., Pampanelli S., Lalli C., del Sindaco P., Di Vincenzo A., Rambotti A.M., Modarelli F., Epifano L., Kassi G., Perriello G., Brunetti P., Bolli G. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care. 19:1996;945-952.
108. B28) on meal-related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care. 14:1991;571-577.
109. Wiefels K., Gries F.A., Dannehl K. Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp). Horm. Metab. Res. 27:1995;421-424.
110. Nielsen F.S., Jørgensen L.N., Ipsen M., Voldsgaard A.I., Parving H.-H. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia. 38:1995;592-598.
111. Jacobs M.A.J.M., Keulen E.T.P., Kang K., Casteleijn S., Scheffer P., Deville W., Heine R.J. Metabolic efficacy of preprandial administration of Lys(B28),Pro(B29) human insulin analog in IDDM patients. Diabetes Care. 20:1997;1279-1286.
112. Bergis K., Schimers S., Gudat U., Kuhn-Röpke A., Trautmann M.E., Pfützner A. Meal composition at breakfast and treatment with insulin lispro (abstract). Diabetologia. 39(Suppl. 1):1996;A223.
113. Burge M.R., Castillo K.R., Schade D.S. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care. 20:1997;152-155.
114. Heinemann L., Heise T., Wahl L.C., Trautmann M.E., Ampudia J., Starke A.A.R., Berger M. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28),Pro(B29)] human insulin. Diabetic Med. 13:1996;625-629.
115. Burge M.R., Waters D.L., Holcombe J.H., Schade D.S. Prolonged efficacy of short acting insulin lispro in combination with human ultralente in insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;920-924.
116. Garg S.K., Carmain J.A., Braddy K.C., Anderson J.H., Vignati L., Jennings M.K. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabetic Med. 13:1996;47-52.
117. J.H. Anderson, Jr., R.L. Brunelle, V.A. Koivisto, M.E. Trautmann, L. Vignati, R. DiMarchi, Multicenter Insulin Lispro Study Group, Improved mealtime treatment of diabetes mellitus using an insulin analogue, Clin. Ther. 19 (1997) 62-72.
118. Ebeling P., Jansson P.-A., Smith U., Lalli C., Bolli G.B., Koivisto V.A. Strategies toward improved control during lispro therapy in IDDM. Diabetes Care. 20:1997;1287-1289.
119. Anderson J.H., Brunelle R.L., Keohane P., Koivisto V.A., Trautmann M.E., Vignati L., DiMarchi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch. Intern. Med. 157:1997;1249-1255.
120. Karsidag K., Satman I., Dinccag N., Altuntas Y., Karadeniz S., Yilmaz M.T. Comparison of metabolic control in IDDM with two different intensive regimens of [Lys(B28), Pro(B29)]-human insulin (Lispro) plus NPH insulin (abstract). Diabetologia. 39(Suppl. 1):1996;A222.
121. Feinglos M.N., Thacker C.H., English J., Bethel M.A., Lane J.D. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care. 20:1997;1539-1542.
122. Schernthaner G., Wein W., Sandholzer K., Equiluz-Bruck S., Birkett M. Postprandial use of insulin lispro: a new therapeutic option in the treatment of type 1 diabetic patient? (abstract). Diabetologia. 39(Suppl. 1):1996;A24.
123. Stiller R., Niederreiter B., Friederich M., Standl E., Trautmann M.E., Haslbeck M. Postprandial versus preprandial substitution of the short acting insulin analogue lispro (abstract). Diabetologia. 38(Suppl. 1):1995;A190.
124. Rami B., Schoeber E. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. Eur. J. Pediatr. 156:1997;838-840.
125. Strachan M.W.J., Frier B.M. Optimal time of administration of insulin lispro. Importance of meal composition. Diabetes Care. 21:1998;26-31.
126. Ahmed A.B.E., Home P.D. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Diabetes Care. 21:1998;32-37.
127. Pöyry K., Kostamo E., Karonen S.-L. The effect of Finnish sauna on the absorption of short-acting insulin analogue (abstract). Diabetes. 44(Suppl. 1):1995;106A.
128. Tuominen J.A., Karonen S.-L., Melamies L., Bolli G., Koivisto V.A. Exercise-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia. 38:1995;106-111.
129. Tuominen J.A., Karonen S.L., Melamies L., Bolli G., Koivisto V.A. Exercise-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue. Diabetes Spectrum. 9:1996;240-241.
130. Antsiferov M., Woodworth J.R., Mayorov A., Ristic S., Dedov I. Within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin (abstract). Diabetologia. 38(Suppl. 1):1995;A190.
131. Vignati L., Anderson J.H., Scwast S., Symanowski S. Twice daily lispro results in less glucose variability compared to human regular insulin (abstract). Diabetologia. 38(Suppl. 1):1995;A191.
132. Kotsanos J.G., Vignati L., Huster W., Andrejasich C., Boggs M.B., Jacobson A.M., Marreto D., Mathias S.D., Patrick D., Zalani S., Anderson J. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care. 20:1997;948-958.
133. Berger M., Heinemann L. Are presently available insulin analogues clinically beneficial? Diabetologia. 40:1997;S91-S96.
134. Bohannon N.J.V. Benefits of lispro insulin. Control of postprandial glucose levels is within reach. Postgrad. Med. 101:1997;73-80.
135. Shaw K. Clinical experience of a rapid-acting insulin analogue (insulin lispro). Pract. Diabetes Int. Suppl. 14:1997;S1-S12.
136. Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care. 20:1997;1357-1359.
137. Henrich H.R., Unger H., Trautmann M.E. Severe insulin resistance treated with insulin lispro. Lancet. 348:1996;1248-1248.
138. Lahtela J.T., Knip M., Paul R., Antonen J., Salmi J. Severe antibody-mediated human insulin resistance: Successful treatment with the insulin analog lispro. Diabetes Care. 20:1997;71-73.
139. Bastyr III E.J., Holcombe J.H., Anderson J.H., Clore J.N. Mixing insulin lispro and ultralente insulin. Diabetes Care. 20:1997;1047-1048.
140. B29 human insulin to extend formulation applications, Abstr. Papers Am. Chem. Soc. 211(1/2) (1996) abstract No. 180.
141. Janssen M.M.J., Casteleijn S., Devillé W., Popp-Snijders C., Roach P., Heine R.J. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. Diabetes Care. 20:1997;1870-1873.
142. Radziuk J.R., Bradley B., Welsh L., De Filippis M.R., Roach P. Neutral protamine lispro: activity profile of s.c. administration with and without admixture of soluble lispro (abstract). Diabetologia. 39(Suppl. 1):1996;A224.
143. Weyer C., Heise T., Heinemann L. Insulin Aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 20:1997;1612-1614.
144. Hanaire H., Bringer J., Lassmann-Vague V., Jeandidier N., Meyer L., Blin P., Tauber J.P., Augendre B. Improvement of HbA1c without increasing hypoglycemia risk in diabetic patients treated with insulin lispro in external pumps (abstract). Diabetologia. 40(Suppl. 1):1997;A10.
145. Furler S.M., Kraegen E.W. Quantitative aspects of subcutaneous insulin absorption. Diabetic Med. 6:1989;657-665.
146. Schlichtkrull J. The absorption of insulin. Acta Paediatr. Scand. Suppl. 207:1977;97-102.
147. L. Langkjær, J. Brange, G.M. Grodsky, R.H. Guy, Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment, J. Control. Release (in press).
148. H.S. Tager, Insulin agonists: the design of analogs for the future, in: H. Rifkin, J.A. Colwell, S.I. Taylor (Eds.), Diabetes 1991, Elsevier, New York, 1991, pp. 82-86.